CD93 Inhibitors

CD93 inhibitors, as defined by the current chemical landscape, are chemicals that can indirectly modulate the activity of the CD93 protein. CD93 is implicated in various cellular processes, such as cell adhesion, migration, and phagocytosis. The inhibition of these processes is not brought about by direct interaction with CD93, but rather through the alteration of signaling pathways that are upstream or downstream of CD93 activation and function.

The chemicals listed above are primarily kinase inhibitors that target various signaling molecules and pathways. For instance, sorafenib and sunitinib are broad-spectrum kinase inhibitors that can disrupt angiogenesis and other cellular processes by inhibiting multiple kinases that may be involved in the regulation of CD93. Erlotinib and gefitinib specifically inhibit the epidermal growth factor receptor (EGFR), which is linked to cell signaling pathways that influence cell adhesion and migration, processes in which CD93 is a participant. Imatinib, dasatinib, and nilotinib are tyrosine kinase inhibitors that also affect various signaling cascades relevant to CD93's role in the cell. The nature of these chemicals' interaction with CD93-related pathways lies in their capacity to alter the intracellular signaling that governs the physiological processes in which CD93 is known to be involved. While none of these chemicals bind to CD93 directly, their actions on various kinases can lead to a modulation of the cellular context in which CD93 operates, thereby affecting its function